Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,167,139,023.14, representing an increase of 18.69% compared to ¥1,825,897,009.74 in the same period last year[11]. - Net profit attributable to shareholders was ¥531,113,560.00, a significant increase of 72.29% from ¥308,262,394.71 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥489,944,263.46, up 83.58% from ¥266,877,653.58 in the previous year[11]. - The basic earnings per share rose to ¥0.8247, reflecting a 72.28% increase compared to ¥0.4787 in the same period last year[11]. - Operating profit for the first half of 2023 was ¥647,895,376.14, up from ¥355,683,396.99 in the first half of 2022, reflecting a significant growth[82]. - The company reported a significant increase in revenue from the South China region, which grew by 49.12% to CNY 316,486,697.93, representing 14.60% of total revenue[21]. - The gross profit margin for the pharmaceutical industry was 72.71%, an increase of 3.93% compared to the previous year[22]. - The company reported a total of 47.81 million yuan in expected daily related transactions with controlled entities for 2023, with actual transactions amounting to approximately 25.006 million yuan as of June 30, 2023[51]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥12,264,996,418.75, a decrease of 2.90% from ¥12,631,382,359.34 at the end of the previous year[11]. - The net assets attributable to shareholders decreased by 2.20% to ¥10,101,692,184.84 from ¥10,329,243,246.41 at the end of the previous year[11]. - Cash and cash equivalents at the end of the reporting period amounted to CNY 5,631,951,352.59, which is 45.92% of total assets, up from 42.51% at the end of the previous year[24]. - The total liabilities decreased to CNY 2,141,962,485.77 from CNY 2,280,591,916.03, indicating a reduction of 6.09%[78]. - The total assets as of June 30, 2023, were CNY 12,264,996,418.75, down from CNY 12,631,382,359.34, representing a decline of 2.91%[78]. - The company's equity attributable to shareholders decreased to CNY 10,101,692,184.84 from CNY 10,329,243,246.41, a decrease of 2.20%[78]. Cash Flow - The net cash flow from operating activities was ¥752,303,456.45, which is a 6.17% increase from ¥708,583,538.34 in the same period last year[11]. - The cash inflow from operating activities totaled ¥2,467,442,535.71 in the first half of 2023, compared to ¥2,066,684,062.90 in the first half of 2022, reflecting an increase of about 19.4%[86]. - The net cash flow from investment activities was ¥167,239,257.54, a decrease of 25.5% compared to ¥224,518,314.12 in the previous period[88]. - The net cash flow from financing activities was -¥391,124,258.26, compared to a positive net flow of ¥64,981,280.27 in the previous period[88]. Product Development and Market Strategy - The company launched new products including the "Peach Blossom Princess" Ejiao cake and the Ejiao instant powder, targeting younger demographics and expanding consumption scenarios[17]. - The company is actively developing new indications for its flagship product, Compound Ejiao Syrup, which has shown significant clinical benefits for cancer-related fatigue[18]. - Dong-E E-Jiao plans to launch two new product lines in the second half of 2023, targeting a market share increase of 5% in the health supplement sector[96]. - The company aims to expand its product matrix by developing more premium traditional Chinese medicine and light health products, exploring "Ejiao+" and "+Ejiao" categories[35]. Environmental and Social Responsibility - The company invested 1.79 million yuan in environmental governance and protection in the first half of 2023[42]. - The company has established two wastewater treatment facilities to ensure compliance with environmental standards[42]. - The company achieved a 100% monitoring rate and compliance rate for wastewater, waste gas, and noise emissions[42]. - Dong-E E-Jiao emphasized its commitment to sustainable practices, with plans to reduce production waste by 30% by 2025[96]. Shareholder Information - The company reported a 43.01% investor participation rate in the first extraordinary shareholders' meeting held on March 13, 2023[36]. - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 23.50% of the total shares, amounting to 151,351,731 shares[67]. - The total number of shares decreased from 654,021,537 to 643,976,824 due to the cancellation of 10,044,713 shares[64]. - The report indicates no significant changes in the number of shareholders, remaining at 48,135[67]. Risk Factors - The company faces long-term risks related to the decline in the population of donkeys due to mechanization and urbanization, impacting the breeding industry[33]. - The company has not experienced any major litigation or arbitration matters during the reporting period[46]. - The company has not engaged in any significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[45]. Financial Management - The company has a total of 140.771 million yuan in entrusted financial management, with no overdue amounts[56]. - The expected return rates for various financial products ranged from 2.55% to 3.64%, with the highest return from the Industrial and Commercial Bank of China at 3.64%[60]. - The company has engaged in multiple financial products with a total investment of 30,000 thousand, yielding a profit of 507.99 thousand[60]. Accounting Policies - The company recognizes cash dividends or profits declared by investees as investment income in the current period[116]. - The company assesses expected credit losses based on a simplified approach for receivables without significant financing components, measuring loss provisions over the entire duration[108]. - The company recognizes revenue when it fulfills its performance obligations, typically upon transfer of control of goods or services to the customer[137].

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-44 东阿阿胶股份有限公司 董 事 会 为更好与广大投资者进行沟通交流，结合工作需要，东阿阿胶股份有限公司 （以下简称"公司"）拟对董事会秘书、证券事务代表及投资者关系的联系方式 进行调整。具体情况如下： 变更前的联系电话及传真：0635-3264069，0635-3260786。 变更后的联系电话及传真：0531-88800423。 以上变更，自本公告发布之日起正式启用。除上述变更外，公司注册地址、 办公地址及电子邮箱等信息保持不变，敬请留意。欢迎广大投资者通过上述渠道 与公司交流沟通。 特此公告。 东阿阿胶股份有限公司 关于变更投资者联系方式的公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二〇二三年八月二十六日 ...

东阿阿胶股份有限公司 | | 往来方与上市公司 | 上市公司核算 | 2023 期初 | 2023 半年度往来累 | 2023 年半年度 | 2023 半年度偿 | 2023 年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来方名称 | 的关联关系 | 的会计科目 | 往来资金余 | 计发生金额（不含 | 往来资金的利息 | 还累计发生金 | 末往来资金余额 | 往来形成原因 | 往来性质 | | | | | 额 | 利息） | （如有） | 额 | | | | | 华润置地（济南）有限公司 | 同一控股股东 | 其他应收款 | 30.40 | 3.82 | | 3.80 | 30.42 | 租赁费 | 经营性往来 | | 青岛正阳特易购置业有限公司 | 同一控股股东 | 其他应收款 | 5.29 | | | 0.00 | 5.29 | 租赁费 | 经营性往来 | | 华润昂德生物药业有限公司 | 同一控股股东 | 其他应收款 | | 60.00 | | 59.96 | 0.04 | 租赁费 | 经营 ...

东阿阿胶股份有限公司独立董事 经审查，2022 年度业绩考核严格按照业绩合同规定的指标及评 分要求，对各项工作的实际达成及加减分项进行评判，符合公司实际 情况。本议案不存在损害公司及股东利益的情形。 作为公司独立董事，我们一致同意本议案，即同意 2022 年度业 绩考核结果。 三、关于聘任董事会秘书的独立意见 公司本次聘任董事会秘书程序，符合相关法律、法规及《公司章 程》等规定，聘任程序合法有效。经审查丁红岩先生的简历及相关资 料，我们认为其任职资格符合相关法律法规规定，具备担任董事会秘 对第十届董事会第二十次会议相关事项发表的独立意见 一、关于关联方资金往来及对外担保事项的独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》等有关规定，作为公司的独立董事，我们对报告期内 控股股东及其关联方占用公司资金及对外担保情况进行了核查，现将 有关问题说明如下： 1.公司与控股股东及其他关联方的资金往来能够严格遵守《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》 的规定，不存在控股股东及其他关联方占用公司资金的情况。 2.公司能够严格控制对外担保风险，不存在为控 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 第十届董事会第二十次会议决议公告 一、董事会会议召开情况 1.东阿阿胶股份有限公司（以下简称"公司"）第十届董事会第二十次会议， 于 2023 年 8 月 22 日以邮件方式发出会议通知。 2.本次董事会会议，于 2023 年 8 月 24 日以通讯表决方式召开。 证券代码：000423 证券简称：东阿阿胶 公告编号：2023-45 东阿阿胶股份有限公司 经与会董事认真讨论，本次会议审议并通过了以下议案： 1.《关于 2023 年半年度报告及摘要的议案》 经审议，董事会认为公司《2023 年半年度报告全文及其摘要》的编制，符 合法律、法规、中国证监会和深圳证券交易所的相关规定。报告内容真实、准确、 完整地反映了公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容，详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《2023 年 半年度报告全文及其摘要》。 表决结果：9 票同意，0 票反对，0 票弃权。 2.《关于 2022 年度业绩考核结果的议案》 公司 2022 年度业绩考核 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-46 东阿阿胶股份有限公司 第十届监事会第十一次会议决议公告 本次会议审议并通过了以下议案： 《关于 2023 年半年度报告及摘要的议案》 经审议，公司《2023 年半年度报告全文及其摘要》的编制，符合法律法规、 中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了 公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。公司《2023 年半年度报告全文及其摘要》是按照中国证监会和深圳证券交易所颁发的信息披 露内容与格式准则等有关要求编制的，所包含内容真实反映了公司财务状况及经 营成果等事项。 具体内容，详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《2023 年半年度报告全文及其摘要》。 表决结果：5 票同意，0 票反对，0 票弃权。 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1.东阿阿胶股份有限公司（以下简称"公司"）第十届监事会第十一次会议， 于 2023 年 8 月 22 日以邮件方式发出会议通知。 2.本次监事会会 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-48 东阿阿胶股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1．会议时间：2023 年 08 月 29 日（星期二）15:30-17:00 4．问题征集：投资者可于 2023 年 8 月 28 日（星期一）12:00 前访问网址 https://eseb.cn/17nskq1FFV6 或使用微信扫描下方程序码，办理预约报名等手 续。在预约报名时可进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 东阿阿胶股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日披露了 《2023 年半年度报告》。为便于广大投资者更加全面深入地了解公司发展战略及 经营业绩等情况，拟定于 2023 年 8 月 29 日举办 2023 年半年度业绩说明会。具 体内容如下： 一、召开时间、地点和方式 1．会议时间：2023 年 8 月 29 日（星期二）15:30-17:00 2．召开方式： ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-43 东阿阿胶股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会无否决议案。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）现场会议召开时间：2023 年 8 月 22 日上午 9 点 （七）会议出席情况：出席会议的股东（或股东代理人）共计123人， 303,396,886股，占上市公司总股份的47.1130％。其中： 通过现场投票的股东10人，代表股份212,720,499股，占上市公司总股份的 33.0323％。 通过网络投票的股东113人，代表股份90,676,387股，占上市公司总股份的 14.0807％。 （二）现场会议召开地点：公司会议室 （三）网络投票时间：通过深圳证券交易所交易系统投票的时间为2023年8 月22日上午9:15—9:25、9:30—11:30，下午13:00-15:00；通过深圳证券交易所 互联网投票系统投票的时间为2023年8月22日9:15-15 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,069,042,839.05, representing a 20.06% increase compared to ¥890,447,328.43 in the same period last year[3] - Net profit attributable to shareholders was ¥230,335,474.70, a significant increase of 100.86% from ¥114,675,694.25 year-on-year[3] - Basic earnings per share were ¥0.3577, reflecting a 100.84% increase compared to ¥0.1781 in the same period last year[3] - Total operating revenue for Q1 2023 reached ¥1,069,042,839.05, an increase of 20.1% compared to ¥890,447,328.43 in Q1 2022[16] - Net profit attributable to shareholders for Q1 2023 was ¥9,046,687,545.35, an increase from ¥8,816,352,070.66 in Q1 2022[15] - The total profit for the first quarter was CNY 278,794,220.63, compared to CNY 158,213,146.85 in the previous year, showing an increase of about 76.1%[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥678,397,600.33, up 51.64% from ¥447,359,353.89 in the previous year[3] - The cash and cash equivalents balance at the end of the period was ¥5,992,481,744.13, a 66.33% increase from ¥3,602,742,355.22 year-on-year[7] - The cash flow from other operating activities was CNY 43,128,942.45, up from CNY 32,087,846.60, reflecting an increase of approximately 34.4%[19] - The company reported a decrease in investment cash flow, with a net cash outflow of CNY 26,269,224.53 compared to a net inflow of CNY 111,184,981.76 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,977,738,444.26, a 2.74% increase from ¥12,631,382,359.34 at the end of the previous year[3] - Total liabilities increased to ¥2,396,442,682.43 in Q1 2023, compared to ¥2,280,591,916.03 in Q1 2022[15] - The company's total current assets at the end of the reporting period amount to 10,181,564,387.63 RMB, an increase from 9,783,733,607.88 RMB at the beginning of the year[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 51,380[8] - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 23.14% of the shares, totaling 151,351,731 shares[9] - The second largest shareholder, Hong Kong Central Clearing Limited, holds 8.93% of the shares, totaling 58,425,607 shares[9] - The total shares held by the top 10 shareholders account for 32.00% of the company's total equity[9] Expenses and Profitability - Total operating costs for Q1 2023 were ¥813,720,355.18, up 7.9% from ¥753,980,213.96 in the same period last year[16] - Research and development expenses for Q1 2023 were ¥22,050,936.58, down from ¥28,843,752.70 in Q1 2022, indicating a focus on cost management[16] - The company experienced a 33.78% increase in taxes and surcharges, driven by higher sales revenue[6] - The company reported a decrease in tax expenses, which were CNY 48,288,902.10 compared to CNY 43,500,813.18 in the previous year, indicating a rise in profitability despite higher revenues[17] Investment and Equity - Investment income decreased by 66.64%, from ¥13,043,620.40 to ¥4,351,746.21, due to differences in the maturity of financial products[6] - The company has a long-term equity investment of 85,500,686.14 RMB, down from 113,617,187.08 RMB at the beginning of the year[13] - The total equity attributable to shareholders reached ¥10,559,578,721.10, compared to ¥10,329,243,246.41 in the previous year[15] Other Financial Metrics - The weighted average return on equity was 2.21%, up from 1.15% year-on-year[3] - The company reported a significant increase in accounts payable, rising to ¥311,729,809.21 from ¥238,112,792.69 year-over-year[16] - The company incurred a credit impairment loss of CNY 6,261,066.73, compared to CNY 841,349.56 in the previous year, indicating an increase in credit risk[17] - The company's inventory at the end of the reporting period is 1,264,051,749.69 RMB, slightly increased from 1,238,592,184.11 RMB at the beginning of the year[13]

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2023-02 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 中信证券、国海证券、招商证券、东北证券、西部证券、中信建投、 申银万国、海通证券、中金公司、兴业证券、天风证券、国泰君安、 | | | 华西证券、西南证券、方正证券、安信证券、广发证券、中泰证券、 | | | 华创证券、华泰证券、东兴证券、东吴证券、申港证券、英大信托、 | | | 英大基金、嘉实基金、富国基金、慎知资产、汇添富基金、德邦资 | | | 管、湘财基金、递归基金、稳泰基金、东方证券资管、兴业基金、东 | | 参与单位名称 及人员姓名 | 方基金、睿远基金、奥博资本、大成基金、招商基金、广发基金、华 | | | 夏基金、建投基金、源峰基金、红筹投资、星石投资、神农投资、永 | | | 域资产、国信投资、建信基金、长盛基金、前海联合基金、阳光资 | | | 管、朋元资管、恒邦兆丰资管、凯丰 ...